Kazia Therapeutics Limited has announced encouraging preliminary clinical responses from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage metastatic triple-negative breast cancer (TNBC). To date, three patients have demonstrated meaningful clinical responses, including two partial responses and one confirmed complete metabolic response. The company reported that paxalisib has been generally well tolerated, with most adverse events assessed as unlikely or unrelated to the drug and predominantly mild to moderate in severity. Kazia plans to expand the study to additional clinical sites in 2026, with targeted enrollment of twelve TNBC patients by the end of 2026 and topline data readout expected in early 2027. The results reported are preliminary and further data are expected to be generated as the study continues.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-023379), on January 27, 2026, and is solely responsible for the information contained therein.